ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity

Overview of attention for article published in Cancer Immunology Research, March 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#36 of 1,433)
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

So far, Altmetric has seen 11 X posts from 7 X users, with an upper bound of 19,071 followers.

RT @Adri_CIR: #AACR21 Wondering how #OncolyticViruses can be used as a cancer therapy? Check out these @CIR_AACR papers for insights into t…

RT @Adri_CIR: #AACR21 Wondering how #OncolyticViruses can be used as a cancer therapy? Check out these @CIR_AACR papers for insights into t…

Learn about #ONCR-177, a next-gen #OV currently being tested in the clinic, and its use as a single agent and in combination with #ImmuneCheckpointBlockade #CIRReviewerStar ⭐ https://t.co/53FSU2DOiK https://t.co/BR0XTgiACt

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 7 additional X posts.